4D Molecular Therapeutics Inc
NASDAQ:FDMT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.87
35.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FDMT stock under the Base Case scenario is 1.08 USD. Compared to the current market price of 7.87 USD, 4D Molecular Therapeutics Inc is Overvalued by 86%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
4D Molecular Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FDMT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
4D Molecular Therapeutics Inc
Balance Sheet Decomposition
4D Molecular Therapeutics Inc
Current Assets | 552.6m |
Cash & Short-Term Investments | 541.9m |
Other Current Assets | 10.7m |
Non-Current Assets | 67.5m |
Long-Term Investments | 35.7m |
PP&E | 29.4m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 19.4m |
Accounts Payable | 3.4m |
Accrued Liabilities | 14m |
Other Current Liabilities | 2m |
Non-Current Liabilities | 12.4m |
Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
4D Molecular Therapeutics Inc
Revenue
|
41m
USD
|
Operating Expenses
|
-248.4m
USD
|
Operating Income
|
-207.4m
USD
|
Other Expenses
|
29m
USD
|
Net Income
|
-178.5m
USD
|
Free Cash Flow Analysis
4D Molecular Therapeutics Inc
USD | |
Free Cash Flow | USD |
FDMT Profitability Score
Profitability Due Diligence
4D Molecular Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
4D Molecular Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FDMT Solvency Score
Solvency Due Diligence
4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FDMT Price Targets Summary
4D Molecular Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for FDMT is 51 USD with a low forecast of 36.36 USD and a high forecast of 86.1 USD.
Dividends
Current shareholder yield for FDMT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
FDMT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).
Contact
IPO
Employees
Officers
The intrinsic value of one FDMT stock under the Base Case scenario is 1.08 USD.
Compared to the current market price of 7.87 USD, 4D Molecular Therapeutics Inc is Overvalued by 86%.